Eplerenone Patent Expiration
Eplerenone is Used for treating hypertension, heart failure, and conditions related to hyperaldosteronism, often in combination with an ACE inhibitor. It was first introduced by Upjohn Us 2 Llc
Eplerenone Patents
Given below is the list of patents protecting Eplerenone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inspra |
US6863902 (Pediatric) | Immediate release eplerenone compositions |
Oct 10, 2020
(Expired) | Upjohn |
| Inspra |
US6410054 (Pediatric) | Immediate release eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6495165 (Pediatric) | Eplerenone compositions having improved bioavailability |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6534093 (Pediatric) | Immediate release eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6558707 (Pediatric) | Immediate release eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US7157101 (Pediatric) | Micronized eplerenone compositions |
Jun 08, 2020
(Expired) | Upjohn |
| Inspra |
US6410524 (Pediatric) | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
May 05, 2020
(Expired) | Upjohn |
| Inspra |
US6747020 (Pediatric) | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
May 05, 2020
(Expired) | Upjohn |
| Inspra | US6863902 | Immediate release eplerenone compositions |
Apr 10, 2020
(Expired) | Upjohn |
| Inspra | US6410054 | Immediate release eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6495165 | Eplerenone compositions having improved bioavailability |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6534093 | Immediate release eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6558707 | Immediate release eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US7157101 | Micronized eplerenone compositions |
Dec 08, 2019
(Expired) | Upjohn |
| Inspra | US6410524 | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
Nov 05, 2019
(Expired) | Upjohn |
| Inspra | US6747020 | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
Nov 05, 2019
(Expired) | Upjohn |
Eplerenone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Eplerenone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Eplerenone and IOP in Healthy Adults | University of Florida | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Early Aldo Blockade in Subclinical PA | Xinjiang Medical University | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE2, PHASE3 |